title: Aldosterone antagonists: silver bullet or just sodium excretion and potassium retention?
abstract: ACE inhibitors or AT(1) antagonists are powerful therapeutic strategies to slow the progression of renal disease. However, they provide only imperfect protection since they cannot always prevent end-stage renal failure. Innovative approaches are needed to keep patients with chronic kidney disease off dialysis. Blockade of the aldosterone pathway may prove to be such a beneficial therapeutic concept.
authors.affiliation: University Hospital of Hamburg, Department of Medicine, Division of Nephrology, Hamburg, Germany. wenzel@uke.uni-hamburg.de
authors.forename: U
authors.initials: U
authors.lastname: Wenzel
mesh_terms: D000450:Aldosterone / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000517:prevention & control*; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D011188:Potassium / Q000378:metabolism*; D012964:Sodium / Q000378:metabolism*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D000450:Aldosterone; D012964:Sodium; D011188:Potassium